Skip to main content

Advertisement

Table 2 Annual Worsening Rate (AWR)

From: IGF-1 in Friedreich’s Ataxia – proof-of-concept trial

FRDA patients N Annual worsening rate CI 95%
Baseline – 3rd four-month period (AWR) 5 -0.40 ± 0.83 -1.28 to 0.48
Control 99 2,05 ± 1,23 1,58 to 2,52